Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PL1000
- Development stage
- Preclinical
- Lead developer
- Palatin Technologies
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
PL1000 is a non-lipidated peptide melanocortin 4 receptor (MC4R) agonist being developed by Palatin Technologies for the treatment of rare and syndromic obesity disorders, such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. Administered via once-weekly subcutaneous injection, PL1000 is designed as a long-acting therapy, with ongoing efforts to optimize a controlled-release formulation. Unlike first-generation MC4R agonists, PL1000 demonstrates potent MC4R agonist activity without activating the melanocortin 1 receptor (MC1R), which is intended to minimize or eliminate MC1R-mediated hyperpigmentation side effects.
02
Targets
MC4R (Melanocortin 4 receptor)
Beyond the preview
Go deeper on PL1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PL1000.